MEK Inhibitor Structural Design for Efficacy and Lower Toxicity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current MEK inhibitors have failed to deliver clinical efficacy expectations against cancer and cancer-related cachexia, and there is a need for a new class of MEK inhibitors that can effectively reverse the MAPK/ERK pathway while minimizing drug-related toxicity.
Innovation Solution
Development of novel MEK inhibitors with specific structural formulas (I, Ia, Ib, Ic, Id, II, IIa, IIb, IIc, IId) that target the MAPK/ERK pathway, potentially reversing cancer-related cachexia and cancer progression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional MEK inhibitors are used to target the MAPK/ERK pathway, then cancer treatment is attempted, but clinical efficacy expectations are not met and drug-related toxicity occurs
Solution Approach 1:
The patent modifies the chemical structure of MEK inhibitors by changing molecular parameters - specifically incorporating apyrimidyl groups at the R1 position and varying substituents at R2-R6 positions. These structural parameter changes result in new compounds that achieve better clinical efficacy while reducing toxicity, resolving the contradiction between effective cancer treatment and drug-related harmful effects
Solution Approach 2:
The patent creates composite molecular structures by combining specific functional groups - the core MEK inhibitor scaffold with apyrimidyl groups and various substituents (R2-R6). This composite approach allows optimization of both efficacy and safety profiles, producing MEK inhibitors that overcome the limitations of conventional single-structure agents
2Reliability
If MEK inhibitors are used to treat cancer, then cancer progression is targeted, but complete reversal of the MAPK/ERK pathway is not achieved
Solution Approach 1:
The patent employs parameter changes in molecular structure - specifically using apyrimidyl groups at R1 and varying R2-R6 substituents - to enhance the inhibitor's ability to reverse the MAPK/ERK pathway. These structural modifications enable more complete pathway inhibition, achieving better treatment effectiveness and cancer progression reversal
3Reliability
If existing MEK inhibitors are used to address cancer cachexia, then muscle mass loss is targeted, but significant weight loss and poor outcomes persist
Solution Approach 1:
The patent modifies MEK inhibitor structure by incorporating apyrimidyl groups and varying substituents (R2-R6) to optimize the drug's effect on cancer cachexia. These parameter changes enable better reversal of muscle mass loss and weight loss associated with cachexia, addressing the persistent poor outcomes seen with conventional inhibitors
Data Source
AI summary
The present disclosure provides compounds, compositions containing such compounds, and methods of designing, developing, producing and preparing compounds represented by general Formula (I), including pharmaceutically acceptable salts thereof or a synthetic intermediate thereof:The compounds act as MEK inhibitors and are capable of displaying one or more beneficial therapeutic effects, including treating cancer.